Diabetes Daily Report: 01/18/2024

A Phase 3a international, multicentre trial in a Korean population with type 2 diabetes compared once-weekly semaglutide with once-daily sitagliptin as metformin add-on (1). The study included 110 Korean adults and found a greater reduction in HbA1c and body weight with semaglutide 0.5 mg (-1.6%, -2.7 kg) and 1.0 mg (-1.8%, -4.8 kg) versus sitagliptin (-0.9%, 0.5 kg). More participants achieved HbA1c targets and ≥5% weight loss with semaglutide compared to sitagliptin. No new safety concerns were observed. (NCT03061214).

Reference

Lee BW, Cho YM, Kim SG, Ko SH, Lim S, Dahaoui A, Jeong JS, Lim HJ, Yu JM. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes. Diabetes Ther. 2024 Jan 18. doi: 10.1007/s13300-023-01515-0. Epub ahead of print. PMID: 38236431.